Cidofovir 西多福韦; GS 0504; HPMPC; (S-HPMPC)|cas:113852-37-2|西域试剂

Cidofovir 西多福韦; GS 0504; HPMPC; (S-HPMPC),99.15%

产品编号：Bellancom-17438| CAS NO：113852-37-2| 分子式：C₈H₁₄N₃O₆P| 分子量：279.19

Cidofovir可通过抑制病毒DNA聚合酶活性以控制巨细胞病毒CMV复制。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-17438	￥450.00	杭州北京（现货）
Bellancom-17438	￥900.00	杭州北京（现货）
Bellancom-17438	￥1400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cidofovir 西多福韦; GS 0504; HPMPC; (S-HPMPC)

产品介绍

Cidofovir (GS 0504) 是一种无环单磷酸核苷酸类似物，CMV 抑制剂，具有抗病毒活性。Cidofovir 可通过选择性抑制病毒 DNA 聚合酶 (DNA polymerase) 来抑制巨细胞病毒 (CMV) 复制。Cidofovir 可诱导细胞凋亡 (apoptosis)，用于巨细胞病毒性视网膜炎、疱疹、癌症研究。Cidofovir 还具有抗正痘病毒 (orthopoxvirus) 和抗天花病毒活性。

生物活性

Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer. Cidofovir also has anti-orthopoxvirus and anti-variola activities^[4].

体外研究

Cidofovir (5-100 μM, 72 hours) has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC₅₀ of 11 μM, and can reduce Crandell-Reese feline kidney cell counts in a dose-dependent manner.
Cidofovir (10-1000 μM, 24-120 hours) can reduce cancer cell viability and induces apoptosis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	Crandell-Reese feline kidney(CRFK) cells
Concentration:	10-100 μM
Incubation Time:	72 hours
Result:	Reduced CRFK cells by 9.1%.

Cell Viability Assay

Cell Line:	Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells
Concentration:	10-1000 μM
Incubation Time:	24, 48, 72, 96, 120 hours
Result:	Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group.

Apoptosis Analysis

Cell Line:	FTC-133 cells
Concentration:	100 μM
Incubation Time:	96 hours
Result:	Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.

体内研究
(In Vivo)

Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female weanling BALB/c mice infected with cowpox virus (CPV)
Dosage:	100 mg/kg
Administration:	Subcutaneous injection; 3-6 days interval; 21 days
Result:	Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection. Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.

体内研究

Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female weanling BALB/c mice infected with cowpox virus (CPV)
Dosage:	100 mg/kg
Administration:	Subcutaneous injection; 3-6 days interval; 21 days
Result:	Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection. Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.

体内研究

Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female weanling BALB/c mice infected with cowpox virus (CPV)
Dosage:	100 mg/kg
Administration:	Subcutaneous injection; 3-6 days interval; 21 days
Result:	Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection. Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.

性状

Solid

溶解性数据

In Vitro:

H₂O : 3.33 mg/mL (11.93 mM; Need ultrasonic)

DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble or slightly soluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5818 mL	17.9090 mL	35.8179 mL
5 mM	0.7164 mL	3.5818 mL	7.1636 mL
10 mM	0.3582 mL	1.7909 mL	3.5818 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 4.55 mg/mL (16.30 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [Content Brief]

. M Bray, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9. [Content Brief]

. Simona Catalani, et al. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir. Toxicol In Vitro. 2017 Jun;41:49-55. [Content Brief]

[4]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

危害码 (欧洲)	T
风险声明 (欧洲)	25-38
安全声明 (欧洲)	S26-S36
WGK德国	3
海关编码	2933599090

1. 物质的识别

产品名：	Cidofovir
CAS号：	113852-37-2
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Cidofovir
别名：	Vistide; GS 0504; HPMPC
分子式：	C8H14N3O6P
分子量：	279.19

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。